We investigate the frequency of CX3CR1+ CD8+ T cells in PB before and during ICI therapy, and delineate the TCR repertoire in peripheral CX3CR1+ CD8+ T-cell subsets and CD8+ tumor-infiltrating lymphocytes (TILs) using preclinical models. The gene discussed is CD8A; the disease is neoplasm.